NCT05906524 2024-01-10
KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors
Shanghai Kanda Biotechnology Co., Ltd.
Phase 1/2 Unknown
Clinical Trials
5 trialsNCT05840835 2023-08-08
IMMINENT-01
Immix Biopharma, Inc.
Phase 1/2 Unknown
NCT05775874 2023-03-20
A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC
Abbisko Therapeutics Co, Ltd
Phase 2 Unknown
NCT05441046 2022-07-06
Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT04813107 2022-02-22
ANTICIPATE
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Phase 1/2 Unknown